The Role of HBF Decline and its Determinants on Sickle Cell Disease Expression in the First Three Years of Life
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
The Role of HBF Decline and its Determinants on Sickle Cell Disease Expression in the First Three Years of Life
Principal Institution
Muhimbili University/Allied Health Sciences
Principal Investigator(s) (PI)
Nkya, Siana Watoky
Project Contact Information
Email: snkyamtatiro@gmail.com
Year(s) Awarded
2019–2024
Country
Tanzania
Collaborators
University of Pittsburgh
Project Description
Fetal hemoglobin (HbF), a major Sickle Cell Disease modifier, starts to decline prior to birth. The mechanisms underlying HbF decline are not fully understood and it is not clear how this decline influences disease manifestation. This project will investigate this phenomenon in 400 babies with and without SCD who will be followed from birth to three years with the goal of aiding in development of HbF interventions.
Related World Regions / Countries
Related Global Health Research Topics